The KMT2A recombinome of acute leukemias in 2023
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Chromosomal rearrangements of the human KMT2A/MLL gene are associated with de novo as well as therapy-induced infant, pediatric, and adult acute leukemias. Here, we present the data obtained from 3401 acute leukemia patients that have been analyzed between 2003 and 2022. Genomic breakpoints within the KMT2A gene and the involved translocation partner genes (TPGs) and KMT2A-partial tandem duplications (PTDs) were determined. Including the published data from the literature, a total of 107 in-frame KMT2A gene fusions have been identified so far. Further 16 rearrangements were out-of-frame fusions, 18 patients had no partner gene fused to 5’-KMT2A, two patients had a 5’-KMT2A deletion, and one ETV6::RUNX1 patient had an KMT2A insertion at the breakpoint. The seven most frequent TPGs and PTDs account for more than 90% of all recombinations of the KMT2A, 37 occur recurrently and 63 were identified so far only once. This study provides a comprehensive analysis of the KMT2A recombinome in acute leukemia patients. Besides the scientific gain of information, genomic breakpoint sequences of these patients were used to monitor minimal residual disease (MRD). Thus, this work may be directly translated from the bench to the bedside of patients and meet the clinical needs to improve patient survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MLL translocations, histone modifications and leukaemia stem-cell development
Krivtsov, A. V., & Armstrong, S. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2253 · Cited by 1,249 · cited 1×
“These results are in line with previously published data about the frequency and distribution of different KMT2A fusion partner genes [21, 22].”
ResultThe MLL recombinome of acute leukemias in 2017
Meyer, C., Burmeister, T., Gröger, D., Tsaur, G., Fechina, L., Renneville, A., Sutton, R., Venn, N. C., Emerenciano, M., Pombo-de-Oliveira, M. S., et al. (2018) · Leukemia · doi:10.1038/leu.2017.213 · Cited by 676
Self-citationThe MLL recombinome of acute leukemias in 2013
Meyer, C., Hofmann, J., Burmeister, T., Gröger, D., Park, T. S., Emerenciano, M., Pombo de Oliveira, M., Renneville, A., Villarese, P., Macintyre, E., et al. (2013) · Leukemia · doi:10.1038/leu.2013.135 · Cited by 491
Self-citationBalgobind, B. V., Raimondi, S. C., Harbott, J., Zimmermann, M., Alonzo, T. A., Auvrignon, A., Beverloo, H. B., Chang, M., Creutzig, U., Dworzak, M. N., et al. (2009) · Blood · doi:10.1182/blood-2009-04-215152 · Cited by 445 · cited 3×
“AML patients (n= 1116) displayed a more diverse number of partner genes: MLLT3 (n= 339; 30.4%), MLLT10 (n= 209; 18.7%), KMT2A-PTDs (n= 120; 10.7%), ELL (n= 113; 10.1%), AFDN (n= 91; 8.1%), MLLT1 (n= 47; 4.2%), MLLT11 (n= 27; 2.4%), SEPTIN6 (n= 19; 1.7%), MLLT6 (n= 18; 1.6%), EPS15 (n= 15; 1.3%), SEPTIN9 (n= 14; 1.3%),…”
BackgroundInfluentialSelf-citationNew insights to the MLL recombinome of acute leukemias
Meyer, C., Kowarz, E., Hofmann, J., Renneville, A., Zuna, J., Trka, J., Ben Abdelali, R., Macintyre, E., De Braekeleer, E., De Braekeleer, M., et al. (2009) · Leukemia · doi:10.1038/leu.2009.33 · Cited by 407 · cited 9×
“12 LAMC3 Meyer et al. (2009) t-AML 47 t(10;11)(p12.”
InfluentialSelf-citationPui, C.-H., Gaynon, P. S., Boyett, J. M., Chessells, J. M., Baruchel, A., Kamps, W., Silverman, L. B., Biondi, A., Harms, D. O., Vilmer, E., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08782-2 · Cited by 399 · cited 1×
“1) are recurrently associated with the disease phenotype of acute leukemias [1, 2].”
BackgroundThe MLL recombinome of acute leukemias
Meyer, C., Schneider, B., Jakob, S., Strehl, S., Attarbaschi, A., Schnittger, S., Schoch, C., Jansen, M. W. J. C., van Dongen, J. J. M., den Boer, M. L., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404150 · Cited by 271 · cited 7×
“Leukemia (2023) 37:988 – 1005 MLLT10 gene (n= 80; 3.7%), AFDN (46; 2.1%), EPS15 (n= 36; 1.6%), USP2 (n= 21; 0.9%), ELL (n= 1; 0.05%), KMT2A-PTD (n= 1; 0.05%), and 43 other KMT2A rearrangements (ACTN2, ACNT4, 11x AFF3, 2x AFF4, ARHGAP32, BCAS4, BCL9L, 2x BTBD18, 8x CBL, CEP164, CLIP2, CLTA, 2x CLTC, CREBBP, DCP1A, DDX6…”
InfluentialSelf-citationClinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements
Pui, C.-H., Chessells, J. M., Camitta, B., Baruchel, A., Biondi, A., Boyett, J. M., Carroll, A., Eden, O. B., Evans, W. E., Gadner, H., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402883 · Cited by 241 · cited 1×
“1) are recurrently associated with the disease phenotype of acute leukemias [1, 2].”
BackgroundWang, Z., Song, J., Milne, T. A., Wang, G. G., Li, H., Allis, C. D., & Patel, D. J. (2010) · Cell · doi:10.1016/j.cell.2010.05.016 · Cited by 201 · cited 1×
“Binding of PHD3 to H3K4me2/3 peptides is greatly enhanced by the adjacent bromodomain [72], but binding of the prolyl-peptidyl isomerase CYP33/PPIE confers a cis-trans isomerization of proline1665.”
BackgroundXia, Z.-B., Anderson, M., Diaz, M. O., & Zeleznik-Le, N. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1436338100 · Cited by 194 · cited 1×
“PHD3 has an important dual function, because it either binds to the CYP33/PPIE protein [69, 70] or to methylated lysine-4 residues of histone H3 [71].”
Background
Cited by
Conn, V. M., Chinnaiyan, A. M., & Conn, S. J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00721-7 · Cited by 258
Histone methyltransferase KMT2A: developmental regulation to oncogenic transformation
Ogino, J., & Dou, Y. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107791 · Cited by 21
Metadata
- Authors
- Meyer, C., Larghero, P., Almeida Lopes, B., Burmeister, T., Gröger, D., Sutton, R., Venn, N. C., Cazzaniga, G., Corral Abascal, L., Tsaur, G., Fechina, L., Emerenciano, M., Pombo-de-Oliveira, M. S., Lund-Aho, T., Lundán, T., Montonen, M., Juvonen, V., Zuna, J., Trka, J., Ballerini, P., Lapillonne, H., Van der Velden, V. H. J., Sonneveld, E., Delabesse, E., de Matos, R. R. C., Silva, M. L. M., Bomken, S., Katsibardi, K., Keernik, M., Grardel, N., Mason, J., Price, R., Kim, J., Eckert, C., Lo Nigro, L., Bueno, C., Menendez, P., zur Stadt, U., Gameiro, P., Sedék, L., Szczepański, T., Bidet, A., Marcu, V., Shichrur, K., Izraeli, S., Madsen, H. O., Schäfer, B. W., Kubetzko, S., Kim, R., Clappier, E., Trautmann, H., Brüggemann, M., Archer, P., Hancock, J., Alten, J., Möricke, A., Stanulla, M., Lentes, J., Bergmann, A. K., Strehl, S., Köhrer, S., Nebral, K., Dworzak, M. N., Haas, O. A., Arfeuille, C., Caye-Eude, A., Cavé, H., & Marschalek, R.
- Venue
- Leukemia
- Published
- 2023-04-05
- Volume
- 37
- Issue
- 5
- Pages
- 988-1005
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W4362638831
- Cited by
- 231
- References
- 59
- FWCI
- 52.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The KMT2A recombinome of acute leukemias in 2023. https://app.cochat.ai/papers/10.1038/s41375-023-01877-1
- The paper
- Meyer, C., Larghero, P., Almeida Lopes, B., Burmeister, T., Gröger, D., Sutton, R., Venn, N. C., Cazzaniga, G., Corral Abascal, L., Tsaur, G., Fechina, L., Emerenciano, M., Pombo-de-Oliveira, M. S., Lund-Aho, T., Lundán, T., Montonen, M., Juvonen, V., Zuna, J., Trka, J., . . . Marschalek, R. (2023). The KMT2A recombinome of acute leukemias in 2023. Leukemia. https://doi.org/10.1038/s41375-023-01877-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.